이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 난소암, 나팔관암 또는 원발성 복막암 치료를 위한 펨브롤리주맙 및 카르보플라틴

2026년 10월 29일 업데이트: John Liao, University of Washington

재발성 난소암의 혈청학적 발견 후 진행을 방지하기 위한 카르보플라틴과 병용한 항-PD-1(펨브롤리주맙)의 제2상 연구

This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), when it is detectable by a blood test, CA-125, but not seen on imaging scans. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, but carboplatin has also been shown to stimulate immune responses. Giving pembrolizumab together with carboplatin may work better in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

OUTLINE:

Patients receive carboplatin intravenously (IV) over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo blood sample collection on the trial.

After the completion of study treatment, patients are followed up at 30 days, then every 3 months for year 1, and every 6 months for year 2.

연구 유형

중재적

등록 (실제)

22

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Washington
      • Seattle, Washington, 미국, 98109
        • Fred Hutch/University of Washington Cancer Consortium

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy
  • Have a cancer antigen (CA)-125 that normalized after first-line therapy
  • CA-125 increased to more than twice the upper limit of normal or two times the nadir value after most recent second or later line of treatment
  • Have no measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic
  • All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study
  • Have estimated life expectancy of at least 3 months
  • Be willing and able to provide written informed consent/assent for the trial
  • Be >= 18 years of age on day of signing informed consent
  • Have a performance status of 0 or 1 on the on the Eastern Cooperative Oncology Group (ECOG) performance scale
  • Absolute neutrophil count (ANC) >= 1,500/mcL (performed within 14 days of treatment initiation)
  • Platelets >= 100,000/mcL (performed within 14 days of treatment initiation)
  • Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 14 days of treatment initiation)
  • Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance >= 30 mL/min for subject with creatinine levels > 1.5 x institutional ULN (performed within 14 days of treatment initiation)
  • Total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 X ULN (performed within 14 days of treatment initiation)
  • Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases (performed within 14 days of treatment initiation)
  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or partial thromboplastin time [PTT] is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation)
  • Activated partial thromboplastin time (aPTT) or PTT =< 1.5 X ULN unless patient is receiving anticoagulant therapy (as long as PT or PTT is within therapeutic range of intended use of anticoagulants) (performed within 14 days of treatment initiation)

Exclusion Criteria:

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (if dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment

  • Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune-related adverse events [irAEs]) is allowed

  • Has symptomatic ascites or pleural effusions

  • History of borderline or low malignant potential ovarian cancer

  • Hypersensitivity to pembrolizumab or any of its excipients

  • Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier

  • Has had prior chemotherapy, biologic therapy, targeted small molecule therapy, hormonal therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent

    • Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
    • Note: If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer

  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability

  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease

  • Has an active infection requiring systemic therapy

  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

  • Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment

  • Clinically significant cardiovascular disease

  • Known severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade 3, any history of anaphylaxis, or uncontrolled asthma

  • Has received prior therapy with pembrolizumab

  • Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

  • Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)

  • Has received a live vaccine or live-attenuated vaccine within 30 days of planned start of study therapy. Administration of killed vaccines is allowed

    • Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (carboplatin, pembrolizumab)

Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection on the trial.

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집

Undergo CT

다른 이름들:
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • CT 스캔

Undergo MRI

다른 이름들:
  • MRI

Given IV

다른 이름들:
  • 키트루다
  • MK-3475
  • 람브롤리주맙
  • SCH 900475
  • BCD-201

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Rate of Radiographic Recurrence
기간: At 6 months
At 6 months
Progression Free Survival
기간: Up to 2 years
Up to 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Programmed Cell Death Ligand 1 (PD-L1) Expression
기간: Up to 2 years

Evaluated by immunohistochemistry staining in combined tumor and inflammatory cells in which positivity will be defined by > 3% staining. PD-L1 antibody-stained archival tumor was evaluated by a board-certified pathologist and given a Combined Percent Score (CPS), or the overall percentage of positive cells expressing PD-L1, and a CPS ≥ 3% was defined as PD-L1 positive.

Up to 2 years
Changes in T Cell Activation
기간: Baseline and 18 months

Flow cytometry will be performed on peripheral blood mononuclear cells. A 19-parameter flow cytometry panel was performed and summarized with mean range over time, Baseline and Cycle 3.

Baseline and 18 months
Overall Survival
기간: Up to 2 years

Analyzed using the Kaplan-Meier method. Kaplan-Meier estimates of the survival function with 95% CIs at specific time points (using Greenwood's formula for the standard error) were computed. Comparisons with the historical control OS will be conducted by examining whether the 95% confidence internal covers the historical control proportions.

Up to 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: John B. Liao, MD, PhD, Fred Hutch/University of Washington Cancer Consortium

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 3월 18일

기본 완료 (실제)

2025년 9월 12일

연구 완료 (실제)

2026년 6월 1일

연구 등록 날짜

최초 제출

2020년 5월 6일

QC 기준을 충족하는 최초 제출

2020년 5월 11일

처음 게시됨 (실제)

2020년 5월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 29일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RG1007137
  • P30CA015704 (미국 NIH 보조금/계약)
  • NCI-2020-02615 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • 10312 (기타 식별자: Fred Hutch/University of Washington Cancer Consortium)
  • W81XWH1910009 (기타 보조금/기금 번호: Department of Defense (DOD))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .